Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB08811_nanopub.RAK__VaRHcr0QWFc64wFbnb8JOPrVg2SKaRbu2FnWB7qQ#assertion>. }
Showing items 1 to 16 of
16
with 100 items per page.
- drugbank:DB08811 type drugbank_vocabulary:Drug assertion.
- drugbank:DB08811 label "Tofisopam [drugbank:DB08811]" assertion.
- drugbank:DB08811 seeAlso DB08811 assertion.
- drugbank:DB08811 identifier "drugbank:DB08811" assertion.
- drugbank:DB08811 description "Tofisopam (marketed under brand names Emandaxin and Grandaxin) is a 2,3-benzodiazepine drug which is a benzodiazepine derivative. In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine binding site of the gamma-aminobutyric acid receptor and its psychopharmacological profile differs from such compounds. Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe. The D-enantiomer (dextofisopam) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome." assertion.
- drugbank:DB08811 title "Tofisopam" assertion.
- drugbank:DB08811 bio2rdf_vocabulary:identifier "DB08811" assertion.
- drugbank:DB08811 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB08811 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB08811" assertion.
- drugbank:DB08811 bio2rdf_vocabulary:x-identifiers.org DB08811 assertion.
- drugbank:DB08811 drugbank_vocabulary:drugbank-id "DB08811" assertion.
- drugbank:DB08811 drugbank_vocabulary:x-cas cas:22345-47-7 assertion.
- drugbank:DB08811 drugbank_vocabulary:x-atc atc:N05BA23 assertion.
- drugbank:DB08811 drugbank_vocabulary:x-kegg kegg:D01254 assertion.
- drugbank:DB08811 drugbank_vocabulary:x-pharmgkb pharmgkb:PA165958428 assertion.
- drugbank:DB08811 drugbank_vocabulary:x-wikipedia wikipedia:Tofisopam assertion.